Drugs / Xinmailong Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03785704 | Jan 2019 → Mar 2020 | breast cancer, cardiovascular disorder, chemotherapy-induced toxicity | Peking Union Medical College | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Xinmailong Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03785704 ↗ |
| Modality | Peptide | “the only small molecular bioactive peptide preparation approved by the State Pharmaceutical Administration (P.R.China)” NCT03785704 ↗ |